Characteristics of SARS-CoV-2 Infected Patients with Clinical Outcome During Epidemic Ongoing Outbreak in Wuhan, China

Xiao Min Luo,Wei Zhou,Hongxia Xia,Weize Yang,Xiaojie Yan,Benchao Wang,Tangxi Guo,Lu Ye,Jun Xiong,Zongping Jiang,Yu Liu,Bicheng Zhang
DOI: https://doi.org/10.2139/ssrn.3552812
2020-01-01
SSRN Electronic Journal
Abstract:Background: Since Dec 2019, SARS-CoV-2 has caused about fifty thousand patients and over two thousand deaths in Wuhan, China. We reported characteristics of SARS-CoV-2 infected patients with clinical outcome during epidemic ongoing outbreak in Wuhan. Methods: Data of COVID-19 patients with clinical outcome in a designated hospital in Wuhan, were retrospectively collected from electronic medical records. Characteristics were compared between patients who died or recovered, and between patients with different disease severity. Findings: By Feb 25, 2020, 403 patients were enrolled, 100 died and 303 recovered. The patients who died had higher median age, higher proportion of males and chronic diseases than patients who recovered. Duration from illness onset to admission was 9 (7–12) days. Patients with severe or critical illness had more days from onset to admission compared to those with ordinary illness. Lymphopenia, anemia, hypoproteinemia, and abnormal serum sodium were presented in 52·6%, 54·6%, 69·8%, and 21·8% cases, respectively. Patients who died or with severe/critical illness showed increased white blood cell and neutrophil count, increased serum total bilirubin, creatinine, hypersensitive troponin I, D-dimer, procalcitonin, and C-reactive protein, and decreased red blood cell, lymphocyte, platelet count, and serum albumin on admission compared to those who recovered or with ordinary illness. Interpretation: Multiple homeostasis disturbances were common in patients with severe or critical illness before admission. Early support should be provided, especially for old men with chronic disease, which is vital to restrain disease progression and reduce mortality of COVID-19. Funding Statement: This study received no funding. Declaration of Interests: All authors declare that they have no competing interests. Ethics Approval Statement: This study was approved by the Research Ethics Committee of Renmin Hospital of Wuhan University (approval number: WDRM 2020-K038). Written consent was not required for patients since it was a retrospective, observational study.
What problem does this paper attempt to address?